These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28251179)

  • 21. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2010)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Apr; 68(2):85-104. PubMed ID: 26182813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2007)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Feb; 68(1):1-18. PubMed ID: 25980050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2008)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Feb; 68(1):19-36. PubMed ID: 25980051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ertapenem against selected respiratory pathogens.
    Marchese A; Gualco L; Schito AM; Debbia EA; Schito GC
    J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
    Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
    Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2011)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Apr; 68(2):105-24. PubMed ID: 26182814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2009)].
    Goto H; Kumagai S
    Jpn J Antibiot; 2015 Feb; 68(1):37-54. PubMed ID: 25980052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2001)].
    Shimada K; Oguri T; Igari J; Ikemoto H; Mori T; Kitamura N; Nakano K; Suzuki Y; Yokouchi H; Karasawa Y; Terai T; Yamamoto M; Nakata K; Nakatani T; Inoue H; Nakadate T; Inagawa H; Suwabe A; Obata R; Kudo K; Kobayashi N; Ohno I; Okada S; Hayashi K; Kinoshita T; Konosaki H; Arakawa M; Gejyo F; Kobayashi H; Goto H; Igarashi K; Kawai S; Okada M; Ito A; Sumitomo M; Aoki N; Matsushima T; Niki Y; Suga M; Hirakata Y; Aoki S; Matsuda J; Tosaka M; Nasu M; Nagai H; Kohno S; Tomono K; Miyazaki Y; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2003 Oct; 56(5):365-95. PubMed ID: 14692377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
    Fritsche TR; Sader HS; Cleeland R; Jones RN
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1468-76. PubMed ID: 15793128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP).
    Cilloniz C; Torres A
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):569-576. PubMed ID: 37728376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging resistance problems among respiratory tract pathogens.
    Lister PD
    Am J Manag Care; 2000 May; 6(8 Suppl):S409-18. PubMed ID: 10977480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.